Tumor lysis syndrome primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Tumor lysis syndrome}} | {{Tumor lysis syndrome}} | ||
{{CMG}} | {{CMG}}{{AE}} {{MJK}} | ||
==Overview== | ==Overview== | ||
Effective measures for the primary prevention of tumor lysis syndrome include [[allopurinol]], [[rasburicase]], and IV hydration. | |||
==Prevention== | ==Prevention== | ||
Before initiating chemotherapy for cancer patients, especially lymphomas and leukemias, should receive the following: | |||
*[[Allopurinol]] | |||
*Adequate IV hydration to maintain a high urine output (> 2.5 L/day) | |||
*[[Rasburicase]] (Uricase) is an alternative to allopurinol and is reserved for patients who are high-risk in developing TLS. | |||
*Alkalinization of the urine with [[acetazolamide]] or [[sodium bicarbonate]] is controversial | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 16:48, 23 September 2015
|
Tumor lysis syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tumor lysis syndrome primary prevention On the Web |
|
American Roentgen Ray Society Images of Tumor lysis syndrome primary prevention |
|
Risk calculators and risk factors for Tumor lysis syndrome primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Effective measures for the primary prevention of tumor lysis syndrome include allopurinol, rasburicase, and IV hydration.
Prevention
Before initiating chemotherapy for cancer patients, especially lymphomas and leukemias, should receive the following:
- Allopurinol
- Adequate IV hydration to maintain a high urine output (> 2.5 L/day)
- Rasburicase (Uricase) is an alternative to allopurinol and is reserved for patients who are high-risk in developing TLS.
- Alkalinization of the urine with acetazolamide or sodium bicarbonate is controversial